

List concomitant medications (e.g., stimulants, sodium oxybate):_____

Diagnosis (ICD-10):		
G47.41 Narcolepsy	G47.42 Narcolepsy in conditions classified elsewhere	
G47.411 Narcolepsy with cataplexy	G47.421 Narcolepsy in conditions classified elsewhere w/ cataplexy	
G47.419 Narcolepsy without cataplexy	Other Code: Description	

©2025 CVS Specialty® and/or one of its affiliates. 75-60349A 01/03/25

Wakix (PR) Enrollment Form

Please Complete Patient and Prescriber Information

Prescriber Phone: ____

Patient Name:

Patient Address: Prescriber Name: _ Patient DOB:

Patient Phone:

 $\mathbf{5}$ PRESCRIPTION INFORMATION

Titration to and Maintenance dose of 17.8mg

MEDICATION	STRENGTH, QUANTITY/REFILLS	DOSE & DIRECTIONS
Wakix (pitolisant) oral tablets - Adult Patients	4.45mg tablet #14 17.8mg tablet #23	Titration Dose: Take 8.9mg (two x 4.45mg tablets) by mouth once daily in the morning upon awakening x 7 days; then take 17.8mg (one x 17.8mg tablet) by mouth once daily in the morning upon awakening x 23 days
	Refills: None 4.45mg tablet #21	Titration Dose: Take 4.45mg (one x 4.45mg tablet) by mouth once daily in the morning upon
🗌 Wakix (pitolisant) oral	17.8mg tablet #16	awakening x 7 days; then 8.9mg (two x 4.45mg tablets) by mouth once daily in the morning upon
tablets - Pediatric Patients	Refills: None	awakening x 7 days; then take 17.8mg (one x 17.8mg tablet) by mouth once daily in the morning upon awakening x 16 days
Wakix (pitolisant) oral tablets	17.8mg tablet #30 Refills:	Maintenance Dose: Take 17.8mg (one x 17.8mg tablet) by mouth once daily in the morning upon awakening - The maximum recommended dosage for pediatric patients weighing <40 kg is 17.8mg once daily

Titration to and Maintenance dose of 35.6mg

MEDICATION	STRENGTH, QUANTITY/REFILLS	DOSE & DIRECTIONS
Wakix (pitolisant) oral tablets – Adult Patients	4.45mg tablet #14 17.8mg tablet #39 Refills: None	Titration Dose: Take 8.9mg (two x 4.45mg tablets) by mouth once daily in the morning upon awakening x 7 days; then take 17.8 mg (one x 17.8mg tablet) by mouth once daily in the morning upon awakening x 7 days; then take 35.6mg (two x 17.8mg tablets) by mouth once daily in the morning upon awakening x 16 days
Uwakix (pitolisant) oral tablets – Pediatric Patients	4.45mg tablet #21 17.8mg tablet #25 Refills: None	Titration Dose: Take 4.45mg (one x 4.45mg tablet) by mouth once daily in the morning upon awakening x 7 days; then take 8.9mg (two x 4.45mg tablets) by mouth once daily in the morning upon awakening x 7 days; then take 17.8mg (one x 17.8mg tablet) by mouth once daily in the morning upon awakening x 7 days; then take 35.6mg (two x 17.8mg tablets) by mouth once daily in the morning upon awakening x 9 days
Wakix (pitolisant) oral tablets	17.8mg tablet #60 Refills:	Maintenance Dose: Take 35.6mg (two x 17.8mg tablets) by mouth once daily in the morning upon awakening - The maximum recommended dosage for pediatric patients weighing <40 kg is 17.8mg once daily

Non-Standard Dosing

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Wakix (pitolisant) oral tablets	ıt)	Other:	Quantity:
			Refills:

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

Prescriber's Signature: Date: Date:	Prescriber's Signature: Date:
Do Not Substitute/No Substitution/DAW/May Not Substitute	
"Dispense As Written"/Brand Medically Necessary/	May Substitute/Product Selection Permitted/Substitution Permissible

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty® Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty® and/or one of its affiliates.

©2025 CVS Specialty® and/or one of its affiliates. 75-60349A 01/03/25